NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-04 18:47இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Apollo Hospitals released its investor presentation for the quarter ended September 30, 2026 (Q2 FY27). The presentation outlines the composite scheme for its proposed NewCo (combining Apollo HealthCo, Telehealth, and Keimed), where AHEL plus its shareholders will hold a combined 59.6% effective interest. For NewCo, the company expects to reach an annualized run-rate of ₹25,000 Cr in revenue and ₹1,500 Cr in EBITDA by Q4 FY27, with an estimated listing targeted for Q4 FY27. Proforma combined H1 FY27 revenue for the entity stood at ₹11,201.5 Cr with an EBITDA of ₹624.7 Cr (5.6% margin).
உச்சம் நம்பிக்கை
என்ன மாறியதுApollo Hospitals submitted its comprehensive quarterly investor presentation outlining Q2 FY27 performance and the corporate restructuring roadmap for its omni-channel healthcare platform.
ஏன் இது முக்கியம்The listing and restructuring of NewCo (Apollo HealthCo + Keimed) unlocks value for pharmacy and digital assets while streamlining distribution operations.
📅 குறுகிய காலம்Informational release post quarterly earnings; near-term focus will remain on operational metrics and pharmacy growth updates from the analyst call.
📈 நீண்ட காலம்Demerger and planned listing of NewCo by Q4 FY27 represents a structural value-unlocking catalyst for the retail pharmacy and digital health verticals.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval delays for the composite scheme of arrangement
Continued digital operating costs and cash burn from Apollo 24/7 (INR 158.1 Cr in H1 FY27)
👀 கவனிக்க வேண்டியவை
Track the regulatory approvals and timeline leading up to the targeted Q4 FY27 listing of NewCo, as well as digital cash burn trends in Apollo 24/7.
Q2 Standalone PAT up 13.3% YoY to ₹475.7 Cr; Closes ₹850 Cr Divestment to Cloudnine
Apollo Hospitals reported its Q2 FY27 standalone results with revenue from operations rising 23.2% YoY to ₹2,902.9 Cr (₹29,029 million) and standalone PAT up 13.3% YoY to ₹475.7 Cr (₹4,757 million). The company also announced the completion of the divestment of its subsidiaries ASHPL and AFCPL to Kids Clinic India (Cloudnine) for an enterprise value of ~₹850 Cr, receiving ₹765 Cr in cash and an effective 9.9% equity stake in Cloudnine valued at ₹85 Cr. Additionally, Dr. Madhu Sasidhar will step down as President & CEO of the Hospitals Division effective November 14, 2026, alongside new senior leadership appointments.
உச்சம் நம்பிக்கை
என்ன மாறியதுApollo completed its divestment of fertility and specialty hospital entities to Cloudnine for ₹850 Cr EV and announced the departure of its Hospital Division CEO.
ஏன் இது முக்கியம்The deal monetizes non-core operations, bringing in ₹765 Cr in cash while retaining a 9.9% strategic stake, whereas the solid Q2 earnings reflect continuing double-digit topline expansion.
Standalone Revenue (Q2): ₹2,902.9 கோடிStandalone PAT (Q2): ₹475.7 கோடிCloudnine Divestment Enterprise Value: ₹850 கோடிCash Received from Divestment: ₹765 கோடிDivestment Cash vs TTM PAT: ~35.2%
📅 குறுகிய காலம்Markets will likely react positively to the cash inflow from the completed divestment and consistent revenue growth, while watching for smooth hospital operations post the CEO transition.
📈 நீண்ட காலம்Consolidation into core multi-specialty hospitals while monetizing secondary assets helps fund the planned addition of 3,500-4,300 beds and supports long-term return metrics.
⚠ அபாய எச்சரிக்கைகள்
Key management transition risk with the exit of the Hospital Division CEO
Integration and valuation performance of the 9.9% unlisted stake in Kids Clinic India Limited
👀 கவனிக்க வேண்டியவை
Track the deployment of the ₹765 Cr cash proceeds towards ongoing bed expansions and observe the leadership transition execution under the Managing Director's Project Management Office.
Apollo Hospitals Targets ₹25,000 Cr HealthCo Revenue Run Rate by Q4 FY27
Apollo Hospitals (AHEL) has provided a strategic update on its HealthCo and Keimed merger, reporting a combined proforma revenue of ₹5,346.8 Cr for Q1 FY27. The company is targeting a massive annualized revenue run rate of ₹25,000 Cr for this integrated entity by Q4 FY27, with expected EBITDA margins of 6.5-7.0%. AHEL expects to list the 'New Co' (HealthCo) by Q4 FY27, maintaining a 59.2% majority stake. Digital 24/7 operating costs for the quarter stood at ₹81.1 Cr as the segment moves toward profitability.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the listing timeline for its integrated pharmacy and digital business (HealthCo) for Q4 FY27 and set a clear ₹25,000 Cr revenue run-rate target.
ஏன் இது முக்கியம்The consolidation and listing of HealthCo simplify the corporate structure and create a massive integrated healthcare platform, potentially leading to a valuation re-rating of the parent company.
Combined Q1 Revenue: ₹5,346.8 கோடிTarget Annualized Revenue (Q4 FY27): ₹25,000 கோடிAHEL Stake in New Co: 59.2%Digital 24/7 Op Cost (Q1): ₹81.1 கோடிTarget EBITDA Margin: 6.5% - 7.0%
📅 குறுகிய காலம்The market is likely to view the clarity on the listing timeline and aggressive revenue targets for the pharmacy business as a positive development.
📈 நீண்ட காலம்The successful integration of Keimed and the listing of HealthCo represent a structural shift toward a dominant omni-channel healthcare player in India.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approval delays for the merger
Execution risk in achieving the ₹25,000 Cr run rate
Continued cash burn in digital operations
👀 கவனிக்க வேண்டியவை
Monitor the NCLT and shareholder approval process for the Keimed merger and the specific listing timeline in Q4 FY27, which serves as a major value-unlocking catalyst.
Apollo Hospitals Q1 Standalone PAT up 25.5% to ₹385 Cr; FMCG Slump Sale Approved
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue growing 22.5% YoY to ₹2,656.1 Cr. Standalone PAT rose 25.5% to ₹385.2 Cr, driven by a 20.2% increase in EBITDA to ₹656.2 Cr. The board also approved a slump sale of the FMCG and wellness distribution business from its material subsidiary, Apollo Healthco, to a new wholly-owned subsidiary, Apollo Consumer Products Ltd. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுApollo reported its Q1 FY27 standalone results and initiated a corporate restructuring to move its FMCG distribution business into a dedicated subsidiary.
ஏன் இது முக்கியம்The strong standalone growth reflects robust hospital operations, while the slump sale of the FMCG unit indicates a strategic move to streamline the retail and distribution business structure.
Standalone Revenue (Q1 FY27): ₹2,656.1 கோடிStandalone PAT (Q1 FY27): ₹385.2 கோடிStandalone EBITDA: ₹656.2 கோடிQ1 Standalone Revenue vs TTM Revenue: 10.53%ESOP Grant (Shares): 46,798
📅 குறுகிய காலம்The stock is likely to react positively to the double-digit growth in standalone revenue and profitability.
📈 நீண்ட காலம்The company's focus on high-end surgical cases, pharmacy expansion, and narrowing digital platform losses supports a positive long-term outlook.
⚠ அபாய எச்சரிக்கைகள்
Regulatory changes in healthcare pricing
Continued cash burn in the Apollo 24/7 digital platform
👀 கவனிக்க வேண்டியவை
Investors should monitor the consolidated results to assess the impact of Apollo 24/7's narrowing losses and the execution of the planned 4,300-bed capacity expansion.
25.5% PAT Growth: Apollo Hospitals Reports Q1 FY27 Standalone Revenue of ₹2,656 Cr
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue from operations reaching ₹2,656.1 Cr, a 22.5% increase from ₹2,167.9 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 25.5% YoY to ₹385.2 Cr, while EBITDA rose 20.2% to ₹656.2 Cr. The company also announced a strategic slump sale of its FMCG and wellness undertaking from its subsidiary Apollo Healthco to a new wholly-owned subsidiary, Apollo Consumer Products Limited. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
உச்சம் நம்பிக்கை
என்ன மாறியதுApollo Hospitals reported its Q1 FY27 standalone financial results, initiated a corporate restructuring of its FMCG business, and appointed new statutory auditors for a future term.
ஏன் இது முக்கியம்The strong standalone growth reflects robust demand in hospital services and improved operational efficiency. The slump sale of the FMCG business suggests a strategic move to streamline consumer-facing operations for better focus or potential monetization.
Standalone Revenue (Q1 FY27): ₹2,656.1 கோடிStandalone PAT (Q1 FY27): ₹385.2 கோடிEBITDA (Q1 FY27): ₹656.2 கோடிYoY Revenue Growth: 22.5%YoY PAT Growth: 25.5%ESOP Grant: 46,798 பங்குகள்
📅 குறுகிய காலம்The stock may react positively to the double-digit growth in standalone revenue and profitability, which exceeded the previous year's performance.
📈 நீண்ட காலம்The company's focus on high-end surgical mix, bed expansion, and the narrowing losses in the digital segment support a positive structural outlook over the next few years.
⚠ அபாய எச்சரிக்கைகள்
Regulatory changes in healthcare pricing
Execution risk of the 4,300-bed expansion
Continued cash burn in the digital platform (Apollo 24/7)
👀 கவனிக்க வேண்டியவை
Investors should monitor the consolidated results to assess the performance of the Apollo 24/7 digital platform and the impact of the FMCG business restructuring. The execution of the planned 4,300-bed expansion remains a key long-term growth driver.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Apollo Hospitals to seek approval for Rs 750 Cr NCD issuance and Rs 10/share final dividend
Apollo Hospitals has issued a notice for its 45th AGM on August 25, 2026, to approve a final dividend of Rs 10 per share, bringing the total FY26 dividend to Rs 20. A key agenda item is the proposal to raise up to Rs 750 crore through Non-Convertible Debentures (NCDs), representing approximately 3% of TTM revenue. The meeting will also vote on the re-appointment of founder Dr. Prathap C Reddy as Executive Chairman for a two-year term and Smt. Rama Bijapurkar as an Independent Director for five years. These resolutions aim to maintain management continuity and provide flexible capital for the group's operations.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the agenda for its annual shareholder meeting, including a new debt-raising limit and the final dividend declaration for FY26.
ஏன் இது முக்கியம்The Rs 750 crore NCD provides incremental capital for the company's expansion plans (3,500-4,300 beds over 4 years) while maintaining a healthy debt-to-equity ratio of 0.32.
Proposed NCD Issuance: Rs 750 கோடிNCD vs TTM Revenue: ~3.0%Final Dividend: Rs 10 per shareTotal FY26 Dividend: Rs 20 per shareInterim Dividend Payout: Rs 143.78 கோடி
📅 குறுகிய காலம்Likely neutral; the dividend was largely expected and the fundraise is small relative to the company's Rs 1.32 lakh crore market cap.
📈 நீண்ட காலம்Management continuity is critical for the execution of the 4-year bed expansion strategy; the modest debt raise supports growth without over-leveraging.
⚠ அபாய எச்சரிக்கைகள்
Succession planning for the Executive Chairman
Execution risk on the 4,300-bed expansion plan
👀 கவனிக்க வேண்டியவை
Monitor the voting results of the AGM on August 25, 2026, to confirm the approval of the NCD fundraise and leadership re-appointments.
Apollo Hospitals Shareholders Approve Composite Scheme of Arrangement with 90.44% Majority
Apollo Hospitals Enterprise Limited (AHEL) has received approval from its equity shareholders, secured creditors, and unsecured creditors for a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy and digital health business. The resolution was passed with a significant majority, with 90.44% of total equity votes cast in favor. This restructuring is a critical step in the company's long-term strategy to consolidate its pharmacy distribution and digital health ecosystem.
முக்கிய அம்சங்கள்
Equity shareholders approved the scheme with 11.01 crore votes (90.44%) in favor and 1.16 crore votes (9.56%) against.Public institutional investors showed 85.69% support for the resolution, while public non-institutional support was higher at 96.96%.Promoter and promoter group voted 100% in favor of the arrangement with 4.02 crore votes.The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.The meetings were held on June 24, 2026, following directions from the NCLT Chennai Bench.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive milestone toward the successful restructuring of Apollo's pharmacy and digital health business. Continue to monitor for final NCLT sanctions and the subsequent impact on the valuation of the Apollo 24/7 platform.
Apollo Hospitals Concludes NCLT Meetings for Restructuring Scheme with Keimed and Healthco
Apollo Hospitals Enterprise Limited (AHEL) successfully conducted NCLT-mandated meetings on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech Limited to streamline the group's pharmacy distribution and digital health segments. While the secured creditors meeting proceeded smoothly, the unsecured creditors meeting required a 30-minute adjournment to achieve the necessary quorum. This procedural milestone is a critical step toward final regulatory approval for the group's restructuring.
முக்கிய அம்சங்கள்
Meetings held on June 24, 2026, for secured creditors, unsecured creditors, and equity shareholders via video conferencing.Composite scheme involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).Unsecured creditors meeting was adjourned for 30 minutes from 11:00 a.m. to 11:30 a.m. due to initial lack of quorum.Remote e-voting was conducted from June 20 to June 23, 2026, with additional voting provided during the meetings.Final voting results under SEBI Regulation 44(3) are pending and will be submitted separately.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming disclosure of voting results to confirm stakeholder approval and track the timeline for final NCLT sanctioning of the scheme.
Apollo Hospitals Holds NCLT-Convened Meetings for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (APOLLOHOSP) conducted NCLT-convened meetings on June 24, 2026, for its secured creditors, unsecured creditors, and equity shareholders. The meetings were held to seek approval for a composite scheme of arrangement involving Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. While the unsecured creditors' meeting required a 30-minute adjournment to meet quorum requirements, all proceedings were successfully concluded via video conferencing. The final voting results, which will determine the progress of this corporate restructuring, are expected to be released separately.
முக்கிய அம்சங்கள்
Meetings held on June 24, 2026, for Secured Creditors (10:00 AM), Unsecured Creditors (11:00 AM), and Equity Shareholders (2:30 PM).The proposed scheme involves the merger/arrangement of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech with the parent company.Unsecured Creditors meeting was adjourned for 30 minutes due to initial lack of quorum but reconvened at 11:30 AM per NCLT directions.Remote e-voting was conducted from June 20 to June 23, 2026, with additional e-voting provided during the meetings.The scheme is being processed under Sections 230 to 232 of the Companies Act, 2013, following NCLT orders dated March, April, and May 2026.
👀 கவனிக்க வேண்டியவை
Investors should watch for the upcoming disclosure of the formal voting results to confirm if the scheme has received the necessary majority approval from all stakeholder classes.
Apollo Hospitals Clarifies Governance for Healthtech Listing; Promoter Rights Lapse Below 10%
Apollo Hospitals has issued clarifications regarding the governance structure of Apollo Healthtech Limited, the entity to be independently listed following a composite scheme of arrangement. The company has established a 10% fall-away threshold for aggregate promoter nomination rights and a 5% threshold for individual promoter entities. Additionally, a tiered board representation system has been introduced, limiting the number of nominee directors based on shareholding percentages. These measures, including a commitment to 50% board independence under an executive chairperson, aim to address stakeholder concerns and improve transparency.
முக்கிய அம்சங்கள்
Promoter and promoter group will waive all director nomination rights if aggregate shareholding falls below 10%.Individual promoter entities will lose nomination rights if their specific holding falls below 5%.Tiered nomination rights established: 2 directors for 10-15% stake, up to 5 directors for 35% or more stake.Commitment to maintain at least 50% independent directors on the board if an executive chairperson is in place.The scheme involves the arrangement of Apollo Healthco and Keimed Private Limited into Apollo Healthtech for independent listing.
👀 கவனிக்க வேண்டியவை
Investors should view these governance clarifications as a positive step toward institutional-grade management for the new entity. Continue to monitor the timeline for the independent listing of Apollo Healthtech as it represents a significant value-unlocking event for AHEL shareholders.
Apollo Hospitals has provided additional governance and financial clarifications regarding the composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The proposed Apollo Healthtech board will consist of 50% independent directors (6 members) and includes a 10% fall-away threshold for promoter and investor nomination rights. A key feature is an investor-funded 'Upside Agreement' that rewards management with up to 9% of the upside if a 4x Multiple of Invested Capital (MOIC) is achieved, ensuring no cash outflow from the company. This restructuring aims to unlock value through the independent listing of Apollo Healthtech as a focused healthcare platform.
முக்கிய அம்சங்கள்
Apollo Healthtech board will feature 50% independent representation with 6 independent directors and a Lead Independent Director.Investor-funded Upside Agreement provides a maximum 9% reward contingent on achieving a minimum 4x MOIC target.Promoter and investor board nomination rights will lapse if their respective shareholding falls below a 10% threshold.Ms. Shobana Kamineni is proposed as Executive Chairperson of the new entity, subject to NCLT and shareholder approvals.The scheme is designed as a composite unified transaction to integrate Apollo Healthco and Keimed for strategic agility.
👀 கவனிக்க வேண்டியவை
Investors should support the scheme as it clarifies governance standards and aligns management incentives with significant value creation targets (4x MOIC) without financial burden to the company. Monitor the upcoming NCLT-convened shareholder meetings for formal approval of the arrangement.
Apollo Hospitals Schedules NCLT-Convened Meeting for Composite Scheme on June 24, 2026
Apollo Hospitals Enterprise Limited has announced an NCLT-convened meeting on June 24, 2026, to seek shareholder approval for a composite scheme of arrangement. The scheme involves the restructuring and integration of Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. Remote e-voting for shareholders will be available from June 20 to June 23, 2026, with a cut-off date of June 17, 2026. The approval requires a three-fourths majority in value of the voting shareholders and a majority of public shareholders to pass.
முக்கிய அம்சங்கள்
NCLT-convened meeting for equity shareholders scheduled for June 24, 2026, at 2:30 PM via VC/OAVM.Remote e-voting period set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).Cut-off date for determining voting eligibility is June 17, 2026.Quorum for the equity shareholders' meeting is fixed at 35,640 members.Scheme requires approval from 75% in value of voting shareholders and a majority of public shareholders.
👀 கவனிக்க வேண்டியவை
Investors should review the scheme of arrangement details to understand the impact of the Keimed and Healthco integration on the company's valuation. Shareholders are advised to cast their votes during the e-voting window ending June 23.
Apollo Hospitals Sets June 24 Shareholder Meeting for Major Restructuring and Merger Scheme
Apollo Hospitals (AHEL) has scheduled an NCLT-convened meeting for equity shareholders on June 24, 2026, to vote on a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, the merger of Keimed Private Limited, and the involvement of Apollo Healthtech. This consolidation aims to streamline the company's pharmacy distribution and digital health platforms. Shareholders as of the cut-off date of June 17, 2026, are eligible to participate in the voting process via remote e-voting starting June 20, 2026.
முக்கிய அம்சங்கள்
NCLT-convened meeting of equity shareholders scheduled for June 24, 2026, via Video Conferencing.Cut-off date for determining voting eligibility is June 17, 2026.Remote e-voting period is set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Ltd, and Apollo Healthtech.Valuation reports and fairness opinions were finalized in June 2025 by KPMG, BDO, and Axis Capital.
👀 கவனிக்க வேண்டியவை
Investors should review the specific share entitlement ratios provided in the valuation reports to understand the dilutive or accretive impact of the Keimed merger. This is a critical structural change for Apollo's digital and pharmacy ecosystem and requires a vote by June 24.
Apollo Hospitals Merges Cradle & Fertility Units with Cloudnine in INR 1,550 Cr Deal
Apollo Health and Lifestyle Limited (AHLL), a subsidiary of Apollo Hospitals, is merging its 'Apollo Cradle' and 'Apollo Fertility' businesses with 'Cloudnine' to create a dominant maternity and fertility platform. The transaction values AHLL's specific verticals at INR 1,550 Crores, which will be realized through a combination of cash and a 9.9% equity stake in the merged entity. This strategic move makes AHLL the largest non-financial shareholder in the combined platform, which will operate over 55 centers across India. The deal is backed by marquee investors including Temasek and TPG, aiming to synergize operations and expand into Tier 1 and 2 markets.
முக்கிய அம்சங்கள்
AHLL's Mother & Child and Fertility verticals valued at INR 1,550 Crores in the combination deal.Apollo Health and Lifestyle to hold a 9.9% equity stake and a board seat in the combined entity.The combined platform will operate 55+ centers, creating one of India's largest integrated maternity networks.Transaction involves a cash component and is subject to regulatory approvals including the CCI.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant value-unlocking event for Apollo's retail healthcare segment. Monitor the completion of regulatory approvals and the potential for improved margins through this consolidated platform.
Apollo Hospitals FY26 PAT up 15% to ₹1,493 Cr; Divests Units for ₹1,550 Cr
Apollo Hospitals reported a strong performance for FY26, with standalone revenue growing 13.7% to ₹9,326.2 crore and PAT increasing 15% to ₹1,492.6 crore. The company announced a major divestment of its specialty and fertility units to Kids Clinic India (Cloudnine) for an enterprise value of ₹1,550 crore, receiving ₹765 crore in cash and a 9.9% equity stake. A final dividend of ₹10 per share (200%) was recommended, and the board approved the merger of Apollo Hospitals North Ltd into the parent company.
முக்கிய அம்சங்கள்
Standalone Revenue for FY26 rose to ₹9,326.2 crore compared to ₹8,202.1 crore in FY25Net Profit (PAT) grew 15% YoY to ₹1,492.6 crore with an EPS of ₹103.81Divesting ASHPL and AFCPL to Cloudnine for ₹1,550 crore, retaining a 9.9% equity stake in the buyerRecommended a final dividend of ₹10 per equity share (200%) with a record date of August 14, 2026Re-appointed Dr. Prathap C Reddy as Executive Chairman for a further period of two years
👀 கவனிக்க வேண்டியவை
The strong earnings growth and strategic divestment to unlock value in the mother-and-child segment are positive catalysts. Investors should monitor the completion of the Cloudnine transaction and the subsequent impact on consolidated margins.
Apollo Hospitals Q4 FY26 Consolidated Revenue Up 18% YoY; PAT Rises 7%
Apollo Hospitals Enterprise Limited reported an 18% YoY growth in consolidated revenue for Q4 FY26, reaching ’66,055 million. Consolidated EBITDA grew by 36% YoY to ’10,109 million, with margins improving to 15.3%. Profit After Tax (PAT) for the quarter increased by 7% YoY to ’4,120 million, impacted by tax adjustments from the previous year. Additionally, the company announced a strategic combination of its Mother & Child and Fertility businesses with Cloudnine, valuing AHLL's segment at ’1,550 crores.
முக்கிய அம்சங்கள்
Consolidated revenue for Q4 FY26 grew 18% YoY to ’66,055 million.Consolidated EBITDA increased by 36% YoY to ’10,109 million with a margin of 15.3%.Healthcare Services revenue rose 16% YoY to ’32,678 million with an occupancy rate of 68%.Apollo HealthCo total revenue grew 20% YoY to ’25,184 million, while digital cash loss reduced to ’16 crores.AHLL Mother & Child and Fertility businesses to combine with Cloudnine, valued at ’1,550 crores for cash and a 9.9% equity stake.
👀 கவனிக்க வேண்டியவை
Investors should view these results positively due to strong EBITDA growth and the value-unlocking merger of the maternity business with Cloudnine. Monitor the reduction in digital health losses and operational performance of newly commissioned hospital beds.
Apollo Hospitals Assigned ICRA AAA (Stable) Credit Rating for Rs 3,000 Crore Bank Facilities
Apollo Hospitals Enterprise Limited has received new credit ratings from ICRA Limited for its bank facilities totaling Rs 3,000 crore. The rating agency assigned an '[ICRA]AAA (Stable)' rating for long-term fund-based term loans amounting to Rs 2,052 crore. Additionally, unallocated long-term/short-term limits of Rs 948 crore were assigned '[ICRA]AAA (Stable) / [ICRA]A1+' ratings. This highest-tier credit rating reflects the company's exceptionally strong financial profile and robust debt-servicing capability.
முக்கிய அம்சங்கள்
ICRA assigned '[ICRA]AAA (Stable)' rating to Rs 2,052 crore long-term fund-based term loans.Unallocated limits of Rs 948 crore assigned '[ICRA]AAA (Stable) / [ICRA]A1+' ratings.Total bank facilities rated by ICRA stand at Rs 3,000 crore.Major lenders include Bank of India (Rs 769 crore), Axis Bank (Rs 500 crore), and State Bank of India (Rs 318 crore).
👀 கவனிக்க வேண்டியவை
Investors should view this as a highly positive confirmation of Apollo Hospitals' financial health and low credit risk. The AAA rating ensures the company can continue to borrow at competitive interest rates to fund future growth.
Apollo Hospitals Receives NCLT Order to Reschedule Stakeholder Meetings for Composite Scheme
Apollo Hospitals Enterprise Limited has received a certified order from the NCLT Chennai Bench regarding its Composite Scheme of Arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The Tribunal has approved the company's request to reschedule meetings for equity shareholders and creditors to late June 2026. This procedural update is part of the ongoing restructuring to consolidate the company's pharmacy and digital health businesses. The equity shareholders' meeting is now officially set for June 24, 2026.
முக்கிய அம்சங்கள்
NCLT Chennai Bench approved the rescheduling of stakeholder meetings via an order dated May 5, 2026.Equity Shareholders meeting rescheduled from May 27, 2026, to June 24, 2026, at 2:30 PM.Secured Creditors meeting moved to June 24, 2026, at 10:00 AM.Unsecured Creditors meetings rescheduled to various slots on June 24 and June 25, 2026.The scheme involves the integration of Apollo Healthco Limited and Keimed Private Limited into the group structure.
👀 கவனிக்க வேண்டியவை
Investors should note the revised timeline for the corporate restructuring and monitor the voting outcomes of the stakeholder meetings scheduled for June 24-25, 2026.
Apollo Hospitals Receives NCLT Order for Keimed-Healthco Merger; Meetings Set for May 27, 2026
Apollo Hospitals has received the NCLT order regarding its composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. The tribunal has scheduled meetings for equity shareholders and unsecured creditors of the company on May 27, 2026, to vote on the restructuring proposal. This scheme aims to integrate the pharmacy distribution business of Keimed with Apollo's digital health and pharmacy platform. A high consent level of 90.96% from certain secured creditors has already been noted by the tribunal.
முக்கிய அம்சங்கள்
NCLT Chennai Bench issued the order on April 15, 2026, for the composite scheme of arrangement.Equity shareholders' meeting for Apollo Hospitals is scheduled for May 27, 2026, at 2:30 PM.Unsecured creditors' meeting for the company is set for May 27, 2026, at 11:00 AM.Secured creditors' meeting for Applicant Company 1 is scheduled for May 27, 2026, at 10:00 AM.Consent of 90.96% from secured creditors led to the dispensation of meetings for certain applicant entities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the shareholder and creditor meetings on May 27, 2026, as this restructuring is a key driver for value unlocking in Apollo's pharmacy and digital health ecosystem.
Apollo Hospitals Receives NCLT Order to Convene Meetings for Composite Scheme on May 27, 2026
Apollo Hospitals Enterprise Limited (AHEL) has received an order from the NCLT Chennai regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The tribunal has scheduled the meeting for equity shareholders and unsecured creditors of AHEL for May 27, 2026. Although the company sought to dispense with the secured creditors' meeting citing 90.96% consent, the NCLT has directed that the meeting must proceed on May 27, 2026. This procedural step is crucial for the proposed restructuring of the group's pharmacy and digital health businesses.
முக்கிய அம்சங்கள்
NCLT has fixed May 27, 2026, at 2:30 PM for the meeting of Apollo Hospitals' equity shareholders.The meeting for unsecured creditors of Apollo Hospitals is scheduled for May 27, 2026, at 11:00 AM.Tribunal rejected the request to dispense with the secured creditors' meeting despite 90.96% consent already obtained.Meetings for other involved entities (Transferor Companies) are scheduled for May 26, 2026.The scheme remains subject to final approvals from shareholders, creditors, and regulatory authorities.
👀 கவனிக்க வேண்டியவை
Investors should track the outcome of the shareholder meeting on May 27, 2026, as this restructuring is a key milestone for the company's long-term strategy. No immediate portfolio action is required until the voting results and subsequent regulatory clearances are finalized.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
